8-K filing — Lyell Immunopharma, Inc. (LYEL)
Filed: 2026-08-06 AccNo: 0001628280-26-054330 Size: 321 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Stifel Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $36
Stifel analyst Stephen Willey initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $36.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lyell Immunopharma shares are trading higher after Stifel initiated coverage on the stock with a Buy rating and announced a $36 price target.
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.